Interventions for hypertension and stroke

Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow-up

EuroIntervention 2022;17:1536-1537. DOI: 10.4244/EIJ-D-21-00740

Kolja Sievert
Kolja Sievert1, MD; Stefan Bertog1, MD; Björn Söderberg2, MD; Sameer Gafoor1, MD; Ilona Hofmann1, MD; Iris Grunwald1,3, MD; Nalan Schnelle1,4, MD; Horst Sievert1, MD
1. CardioVascular Center Frankfurt CVC, Frankfurt, Germany; 2. Department of Pediatrics at Institute of Clinical Sciences, Gothenburg University, Gothenburg, Sweden; 3. University of Dundee, Dundee, United Kingdom; 4. Klinikum Kassel, Kassel, Germany
Introduction The Carag bioresorbable septal occluder (CBSO; CARAG AG, Baar, Switzerland) is the first interatrial septal occluder with bioresorbable framework.

Methods STUDY DESIGN The study was a single-centre, prospective, single-arm trial. Ethics committee/regulatory approvals were obtained. ClinicalTrials.gov: NCT01960491.

DEVICE DESCRIPTION The CBSO is the first occluder where the metal framework has been replaced with bioresorbable poly(lactic-co-glycolic) acid (PLGA) (Figure 1). The CBSO is self-centering, with two opposing polyester covers attached to a PLGA monofilament framework. The non-bioresorbable polyester fabric is secured to the monofilaments by platinum–iridium markers/sutures. A distal tip made of Phynox ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Letter: The time has come to use attitudinally appropriate terminology when describing cardiac anatomy

Latest news